Indications
Monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
Composition
- Active substance
- linvoseltamab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lynozyfic
- Active substance
- linvoseltamab
- ATC code
- L01FX
- Therapeutic area
- Multiple Myeloma
- Marketing authorisation holder
- Regeneron Ireland Designated Activity Company (DAC)